Key facts
- This page summarizes Christopher J. Tovey's Form 4 filing for Jazz Pharmaceuticals plc (JAZZ).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Jul 2022, 17:17.
Christopher J. Tovey - 05 Jul 2022 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)
- Reporting relationship
- EVP, COO & Managing Director E
- Issuer ticker
- JAZZ
- Reported as of
- 05 Jul 2022
- Net transaction value
- -$833,359
- SEC form
- 4
- Accepted by SEC
- 07 Jul 2022, 17:17:07 UTC
- Prior SEC filing
- 09 May 2022
- Source filing
- View source filing
- Reporting owner signature
- By: /s/Adam Guttmann, as attorney in fact For: Christopher J Tovey
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher J. Tovey filed Form 4 for Jazz Pharmaceuticals plc (JAZZ) on 07 Jul 2022.
Change
- Previous filing in this sequence was filed on 09 May 2022.
- Current net transaction value: -$833,359.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
JAZZ
transaction
Ordinary Shares
Options Exercise
- Transaction value
- $80.64
- Shares
- +4,032
- Change %
- +25%
- Price
- $0.0200*
- Shares after
- 19,872
- Date
- 05 Jul 2022
- Ownership
- Direct
JAZZ
transaction
Ordinary Shares
Sale
- Transaction value
- $645,120
- Shares
- -4,032
- Change %
- -20%
- Price
- $160.00
- Shares after
- 15,840
- Date
- 05 Jul 2022
- Ownership
- Direct
JAZZ
transaction
Ordinary Shares
Sale
- Transaction value
- $188,320
- Shares
- -1,177
- Change %
- -7.4%
- Price
- $160.00
- Shares after
- 14,663
- Date
- 05 Jul 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
JAZZ
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -4,032
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 4,031
- Date
- 05 Jul 2022
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 4,032
- Exercise price
- $0.0200
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Footnote F2
Option to acquire Jazz Ordinary Shares received upon conversion of options to acquire shares of GW Pharmaceuticals PLC ("GW") pursuant to the GW Transaction Agreement among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW dated February 3, 2021 (the "Merger"). The effective date of the Merger was May 5, 2021. Fifty percent of the award will vest and be available for exercise on February 22, 2022 and fifty percent will vest and be available for exercise on February 22, 2023 in accordance with the terms of the Merger.